$110-195k
Generative machine learning methods for medicine
Job no longer available
Generative machine learning methods for medicine
21-100 employees
Job no longer available
$110-195k
21-100 employees
To advance artificial intelligence to eliminate trial and error in medicine.
Clinical trials supporting the development of new drugs typically drag out for a number of years. With the root of this problem being the lack of qualified participants, especially when drugs reach critical phase 3 studies, which often require hundreds or thousands of participants to test the investigational drug.
Machine learning generative AI startup, Unlearn.AI, is looking to tackle this challenge and transform the way clinical trials are performed. The company specializes in clinical trial optimization through its proprietary technology, called the "Digital Twin", which creates a virtual replica of a patient population in order to simulate the effects of different treatments. Through this approach, researchers are able to run clinical trials with smaller sample sizes, reducing the time and costs associated with traditional clinical trials.
Since its inception in 2017, Unlearn.AI has worked with a number of pharmaceutical companies as well as academic institutions in order to improve clinical trial designs and accelerate drug development efforts. With a bright future on the horizon for the AI startup, Unlearn.AI has the potential to revolutionize healthcare, diagnostics, and treatment.

Steph
Company Specialist at Welcome to the Jungle
28% employee growth in 12 months
Feb 2024
$50m
SERIES C
Mar 2023
$15m
LATE VC
Yerba Buena, San Francisco, CA
Charles Fisher
(CEO)Graduated from Harvard University with a Ph.D. in Biophysics. Previously worked as a Machine Learning Engineer at Leap Motion, as well as a Principal Scientist at Pfizer.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
